Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the FDA approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Dr. Wierda reviews how the treatment works, its potential side effects and shares his perspective on what the approval could mean for a broader group of patients in the future.
What Could a New Drug Approval Mean fo... - CLL America Support
What Could a New Drug Approval Mean for CLL Patients?
Written by
mcints
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
A wonderful video with a fantastic Dr.
Jeff
Thanks! He is great!!
Not what you're looking for?
You may also like...
obinutuzumab + venetoclax
Scheduled to start treatment end of the month to have CLL under control.
Felt fine otherwise and...
